.png)
A manufacturing platform for low-dose, high-potency medicines.
A manufacturing platform for medicines conventional processes can't dose reliably — built once, reused across molecules. Post-seed, raising to validate three initial drug targets and position the IP for an early exit.
Tangible IP, a patent-pending method, a bounded exit — the old-fashioned way to build value, not hype.
Sector
Low-dose pharma manufacturing tech
Stage
Post Seed
Exit
Trade sale, targeted 2029
The Opportunity
Making it once is hard. Making it repeatedly, at cost, is harder.
- The Problem — Ultra-low-dose medicines (microgram scale) push conventional powder-mixing manufacturing to its physical limit. Countless high-value molecules are quietly abandoned due to batch variance, soaring control costs, and rejected lots.
- The Market Gap — In-development molecules stalled without a viable, repeatable production method; legacy medicines trapped in costly manufacturing where regulatory and reformulation hurdles deter incumbents from innovating.
- Our Solution — A scalable, patent-pending platform that solves low-dose precision manufacturing, unlocking abandoned targets and protecting margins across both new and established drug markets.
- For Patients — Without a reliable low-dose option, patients are often left splitting tablets or guessing at the right amount. Satio's platform is built to finally give them the dosage accuracy they deserve.
Next Step
The next step is a short management meeting, after which the full business case, budget and development plan are available under a mutual confidentiality agreement.
Request Investor BriefingOr get in touch via info@satio-life-sciences.com